Journal
ALZHEIMERS & DEMENTIA
Volume 10, Issue 6, Pages 684-689Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2014.03.006
Keywords
Dementia; Agreement; Diagnostic criteria; Tau; FDG-PET; Hippocampal atrophy
Categories
Funding
- Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant) [U01 AG024904]
- DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
- National Institute on Aging
- National Institute of Biomedical Imaging and Bioengineering
- Canadian Institutes of Health Research
- Alzheimer's Association
- Alzheimer Drug Discovery Foundation
- BioClinica, Inc
- Biogen Idec
- Bristol-Myers Squibb
- Eisai Inc
- Elan Pharmaceuticals, Inc
- Eli Lilly
- F. Hoffmann-La Roche Ltd
- Genentech
- GE
- Innogenetics
- N.V.
- IXICO Ltd
- Janssen Alzheimer Immunotherapy Research & Development, LLC
- Johnson & Johnson Pharmaceutical Research & Development, LLC
- Medpace, Inc
- Merck Co., Inc.
- Meso Scale Diagnostics, LLC
- NeuroRx Research
- Novartis
- Pfizer
- Piramal Imaging
- Servier
- Synarc Inc
- Takeda Pharmaceutical Company
Ask authors/readers for more resources
New diagnostic criteria for Alzheimer's disease (AD) treat different biomarkers of neuronal injury as equivalent. Here, we quantified the degree of agreement between hippocampal volume on structural magnetic resonance imaging, regional glucose metabolism on positron emission tomography, and levels of phosphorylated tau in cerebrospinal fluid (CSF) in 585 subjects from all phases of the AD Neuroimaging Initiative. The overall chance-corrected agreement was poor (Cohen kappa, 0.24-0.34), in accord with a high rate of conflicting findings (26%-41%). Neither diagnosis nor APOE epsilon 4 status significantly influenced the distribution of agreement between the biomarkers. The degree of agreement tended to be higher in individuals with abnormal versus normal CSF beta-am-yloid (A beta(1-42)) levels. Prospective diagnostic criteria for AD should address the relative importance of markers of neuronal injury and elaborate a way of dealing with conflicting biomarker findings. (C) 2014 The Alzheimer's Association. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available